TG Therapeutics Inc
TGTX
Market Cap$5.57B
Close$
$-27.53
177% downside
Current Fair Value
177% downsideOvervalued by 177% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.57 Billion |
|---|---|
| Enterprise Value | $5.47 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $0.16 |
| Beta | 2.21 |
| Outstanding Shares | 146,677,783 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 131.54 |
|---|---|
| PEG | -89.33 |
| Price to Sales | 17.88 |
| Price to Book Ratio | 35.75 |
| Enterprise Value to Revenue | 14.15 |
| Enterprise Value to EBIT | 83.49 |
| Enterprise Value to Net Income | 139 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About TG Therapeutics Inc
CEO: Michael Weiss